Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

83.67EUR
7:06am EST
Change (% chg)

€0.88 (+1.06%)
Prev Close
€82.79
Open
€83.02
Day's High
€83.80
Day's Low
€82.58
Volume
31,995
Avg. Vol
89,353
52-wk High
€84.09
52-wk Low
€46.01

IPN.PA

Chart for IPN.PA

About

Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs. Its portfolio includes pharmaceutical products divided into four targeted therapeutic areas: Neurology, Endocrinology, Uro-Oncology and Primary Care. In the Neurology segment the Company offers a product called Dysport, in... (more)

Overall

Beta: 0.60
Market Cap(Mil.): €6,917.75
Shares Outstanding(Mil.): 83.56
Dividend: 0.85
Yield (%): 1.03

Financials

  IPN.PA Industry Sector
P/E (TTM): 30.34 29.27 29.99
EPS (TTM): 2.73 -- --
ROI: 13.48 13.52 13.04
ROE: 17.49 14.41 14.18

BRIEF-Ipsen FY net profit rises to 226.6 million euros

* Delivers strong 2016 results and expects further sales growth and margin enhancement for 2017

Feb 23 2017

BRIEF-Ipsen acquires a portfolio of select consumer healthcare products from Sanofi

* Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi

Feb 13 2017

Drugmaker Ipsen to buy some products from Sanofi for 83 million euros

PARIS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

Feb 13 2017

Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg

Feb 12 Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.

Feb 12 2017

BRIEF-Ipsen to acquire Primary Care Platform in Italy from Akkadeas Pharma

* Ipsen to acquire Primary Care Platform in Italy from Akkadeas Pharma

Jan 31 2017

France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal

French drugmaker Ipsen SA said on Monday it would buy some assets of Merrimack Pharmaceuticals Inc , including pancreatic cancer drug Onivyde, for up to $1 billion, barely a month after the U.S. company stopped a breast cancer drug trial.

Jan 09 2017

UPDATE 2-France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal

Jan 9 French drugmaker Ipsen SA said on Monday it would buy some assets of Merrimack Pharmaceuticals Inc , including pancreatic cancer drug Onivyde, for up to $1 billion, barely a month after the U.S. company stopped a breast cancer drug trial.

Jan 09 2017

Ipsen to buy some Merrimack assets for about $1 billion

Jan 8 French drugmaker Ipsen SA said on Monday it would buy some assets of U.S. peer Merrimack Pharmaceuticals Inc, including its pancreatic cancer treatment Onivyde, for about $1 billion.

Jan 08 2017

BRIEF-Ipsen to acquire Oncology Assets from Merrimack Pharmaceuticals

* Ipsen to acquire Oncology Assets from Merrimack Pharmaceuticals

Jan 08 2017

BRIEF-Ipsen Q3 sales up 12.2 pct at 390.6 mln euros

* Reports 12.2% sales growth for the third qtr Of 2016 and raises full year guidance

Oct 26 2016

More From Around the Web

Earnings vs. Estimates